Company Info
Industry | Pharmaceuticals: Major |
---|---|
Sector | Health Technology |
Employees | 476 |
CEO | Dr. Cedric Francois |
Address | 100 5th Avenue , Waltham, MA 02451-8703 |
---|---|
Phone | 1.617.977.5700 |
Website | www.apellis.com |
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Statement Summary
as of 4:00 ET PM 05/20/2022Total Assets (MRQ) | 1.1 B |
---|---|
Total Liabilities (MRQ) | 683.6 M |
Shareholders’ Equity (MRQ) | 462.2 M |
Total Revenue (Annual) | 14.4 M |
Net Income (Annual) | -138.9 M |
Earnings And Estimates
as of 4:00 ET PM 05/20/2022
Current Qtr EPS Estimate | -1.29 |
---|---|
Current FY EPS Estimate | -5.55 |
Long Term EPS Growth Estimate | 19.63 |
Next Expected Earnings Date | 8/4/2022 |
APLS vs S&P 500
as of 05/20/2022Relative To S&P 500 |
APLS | |
---|---|---|
4 Weeks | n/a | n/a |
12 Weeks | n/a | n/a |
YTD | n/a | n/a |
Earnings Surprises
as of 4:00 ET PM 05/20/2022Fiscal Quarter | Estimate | Actual | Surprise |
---|---|---|---|
03/2022 | -1.33 | -1.42 | +6.47% |
12/2021 | -1.54 | -1.61 | +4.67% |
09/2021 | -1.69 | -2.28 | +34.63% |
06/2021 | -1.72 | -2.72 | +58.46% |
03/2021 | -1.64 | -2.32 | +41.76% |
12/2020 | -0.67 | 0.93 | -239.53% |
09/2020 | -1.57 | -1.79 | +14.14% |
06/2020 | -1.33 | -1.57 | +18.29% |
Financial Strength
as of 4:00 ET PM 05/20/2022Pre-Tax Margin | -957.70 |
---|---|
Net Margin | 0.00 |
Operating Margin | -897.00 |
Return On Equity | -273.07 |
Return On Assets | -71.74 |
Inventory Turnover (TTM) | 0.00 |
Sales Growth (MRQ) | n/a |
Ratios
as of 4:00 PM ET 05/20/2022Price/Earnings (TTM) | n/a |
---|---|
Price/Book (MRQ) | 10.32 |
Price/Cash Flow (TTM) | 0.00 |
Book Value (MRQ) | 4.34 |
Quick Ratio (MRQ) | 8.58 |
Current Ratio (MRQ) | 8.85 |
Total Debt/Equity (MRQ) | 1.22 |
Short Interest
as of 4:00 PM ET 05/23/2022% Short - 0.00% | |
% Remaining Float - 100.00% |
Current | Last Month | |
---|---|---|
Short Interest Date | n/a | n/a |
Short Interest Shares | 0 | 0 |
Short Interest Ratio | 0.0 | 0.0 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
---|---|---|
Balance Sheet
M Y | ||||
---|---|---|---|---|
ASSETS | ||||
Cash And Equivalents | 0,0.00 | |||
Receivables | 0,0.00 | |||
Inventories | 0,0.00 | |||
Other Current Assets | 0,0.00 | |||
Total Current Assets | 0,0.00 | |||
Property, Plant & Equipment, Gross | 0,0.00 | |||
Accumulated Depreciation & Depletion | 0,0.00 | |||
Property, Plant & Equipment, Net | 0,0.00 | |||
Intangibles | 0,0.00 | |||
Other Non-Current Assets | 0,0.00 | |||
Total Non-Current Assets | 0,0.00 | |||
TOTAL ASSETS | 0,0.00 | |||
Liabilities & Shareholder Equity | ||||
Accounts Payable | 0,0.00 | |||
Short Term Debt | 0,0.00 | |||
Total Current Liabilities | 0,0.00 | |||
Long Term Debt | 0,0.00 | |||
Deferred Income Taxes | 0,0.00 | |||
Other Non-Current Liabilities | 0,0.00 | |||
Minority Interest | 0,0.00 | |||
Total Non-Current Liabilities | 0,0.00 | |||
Preferred Stock Equity | 0,0.00 | |||
Common Stock Equity | 0,0.00 | |||
Common Par | 0,0.00 | |||
Additional Paid In Capital | 0,0.00 | |||
Cumulative Translation Adjustment | 0,0.00 | |||
Retained Earnings | 0,0.00 | |||
Treasury Stock | 0,0.00 | |||
Other Equity Adjustments | 0,0.00 | |||
Total Capitalization | 0,0.00 | |||
TOTAL EQUITY | 0,0.00 | |||
TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
Total Common Shares Outstanding | 0,0.00 | |||
Preferred Shares | 0,0.00 | |||
Treasury Shares | 0,0.00 | |||
Basic Weighted Shares Outstanding | 0,0.00 | |||
Diluted Weighted Shares Outstanding | 0,0.00 | |||
Number Of Employees | 0,0.00 | |||
Number Of Part-Time Employees | 0,0.00 |
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
---|---|---|
Income Statement
M Y | |
---|---|
Sales | 0,0.00 |
Cost Of Sales | 0,0.00 |
Gross Operating Profit | 0,0.00 |
Selling, General, And Administrative Expenses | 0,0.00 |
Research & Development | 0,0.00 |
Operating Income Before D & A (EBITDA) | 0,0.00 |
Depreciation & Amortization | 0,0.00 |
Interest Income | 0,0.00 |
Other Income - Net | 0,0.00 |
Special Income / Charges | 0,0.00 |
Total Income Before Interest Expenses (EBIT) | 0,0.00 |
Interest Expense | 0,0.00 |
Pre-Tax Income | 0,0.00 |
Income Taxes | 0,0.00 |
Minority Interest | 0,0.00 |
Net Income From Continuing Operations | 0,0.00 |
Net Income From Discontinued Operations | 0,0.00 |
Net Income From Total Operations | 0,0.00 |
Extraordinary Income/Losses | 0,0.00 |
Income From Cum. Effect Of Acct. Change | 0,0.00 |
Income From Tax Loss Carryforward | 0,0.00 |
Other Gains / Losses | 0,0.00 |
Total Net Income | 0,0.00 |
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
Preferred Dividends | 0,0.00 |
Net Income Available To Common | 0,0.00 |
Basic EPS From Continuing Ops. | 0,0.00 |
Basic EPS From Discontinued Ops. | 0,0.00 |
Basic EPS From Total Operations | 0,0.00 |
Basic EPS From Extraordinary Inc. | 0,0.00 |
Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
Basic EPS From Other Gains (Losses) | 0,0.00 |
Basic EPS, Total | 0,0.00 |
Basic Normalized Net Income/Share | 0,0.00 |
EPS From Continuing Ops. | 0,0.00 |
EPS From Discontinued Ops | 0,0.00 |
EPS From Total Ops. | 0,0.00 |
EPS From Extraord. Inc. | 0,0.00 |
EPS From Cum Effect of Accounting Change | 0,0.00 |
EPS From Tax Loss Carfd. | 0,0.00 |
EPS From Other Gains (L) | 0,0.00 |
EPS, Total | 0,0.00 |
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
---|---|---|
Cash Flow Statement
M Y | ||||
---|---|---|---|---|
Cash Flow From Operating Activities | ||||
Net Income (Loss) | 0,0.00 | |||
Operating Gains/Losses | 0,0.00 | |||
Gross Operating Profit | 0,0.00 | |||
(Increase) Decrease In Receivables | 0,0.00 | |||
(Increase) Decrease In Inventories | 0,0.00 | |||
(Increase) Decrease In Other Current Assets | 0,0.00 | |||
(Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
(Increase) Decrease In Other Working Capital | 0,0.00 | |||
Other Non-Cash Items | 0,0.00 | |||
Net Cash From Continuing Operations | 0,0.00 | |||
Net Cash From Discontinued Operations | 0,0.00 | |||
Cash Provided By Investing Activities | ||||
Net Cash From Total Operating Activities | 0,0.00 | |||
Sale Of Property, Plant & Equipment | 0,0.00 | |||
Cash Used For Investing Activities | ||||
Sale Of Short-Term Investments | 0,0.00 | |||
Purchases Of Property, Plant & Equipment | 0,0.00 | |||
Acquisitions | 0,0.00 | |||
Purchases Of Short-Term Investments | 0,0.00 | |||
Other Cash From Investing Activities | 0,0.00 | |||
Cash Provided by Financing Activities | ||||
Net Cash From Investing Activities | 0,0.00 | |||
Issuance Of Debt | 0,0.00 | |||
Cash Used For Financing Activities | ||||
Issuance Of Capital Stock | 0,0.00 | |||
Repayment Of Long-Term Debt | 0,0.00 | |||
Repurchase Of Capital Stock | 0,0.00 | |||
Payment Of Cash Dividends | 0,0.00 | |||
Other Financing Charges, Net | 0,0.00 | |||
Net Cash From Financing Activities | 0,0.00 | |||
Effect Of Exchange Rate Changes | 0,0.00 | |||
Net Change In Cash & Cash Equivalents | 0,0.00 |
Earnings Estimates
as of 4:00 ET PM 05/20/2022Current Qtr (06/2022) |
Next Qtr (09/2022) |
|
---|---|---|
Consensus Estimate | $-1.29 | $-1.35 |
# of Estimates | 15 | 15 |
High Estimate | $-0.95 | $-1.08 |
Low Estimate | $-1.68 | $-1.69 |
Year Ago EPS | $-2.72 | $-2.28 |
Year Over Year Growth Estimate | -52.50% | -40.79% |
Current Yr (12/2022) |
Next Yr (12/2023) |
|
---|---|---|
Consensus Estimate | $-5.55 | $-4.49 |
# of Estimates | 15 | 14 |
High Estimate | $-4.99 | $-1.70 |
Low Estimate | $-7.10 | $-7.31 |
Year Ago EPS | $-8.84 | $-5.55 |
Year Over Year Growth Estimate | -37.17% | -19.25% |
Current Qtr (06/2022) |
Next Qtr (09/2022) |
Current Year (12/2022) |
Next Year (12/2023) |
|
---|---|---|---|---|
Consensus Estimate | $-1.29 | $-1.35 | $-5.55 | $-4.49 |
# of Estimates | 15 | 15 | 15 | 14 |
High Estimate | $-0.95 | $-1.08 | $-4.99 | $-1.70 |
Low Estimate | $-1.68 | $-1.69 | $-7.10 | $-7.31 |
Year Ago EPS | $-2.72 | $-2.28 | $-8.84 | $-5.55 |
Year Over Year Growth Estimate | -52.50% | -40.79% | -37.17% | -19.25% |
Insider Information Summary
as of 04/30/2022% Insiders - 17.20% | |
% Remaining Total Shares - 82.80% |
Current | 1 Month | |
---|---|---|
Net Insider Transaction | 17.55 K | 417.22 K |
Shares Bought | 90.68 K | 462.60 K |
Shares Sold | 73.14 K | 45.38 K |
Insider Activity
Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
---|---|---|---|---|---|---|---|---|---|---|
Latest News
5 Top Stock Gainers for Monday: Discovery, Apellis Pharma
May 17, 2021 4:23 PM EDT
Apellis Jumps on Blood Disease Treatment Approval
May 17, 2021 9:46 AM EDT
Editas Medicine Falls as Goldman Sachs Initiates the Stock at Sell
Apr 16, 2021 11:05 AM EDT
Apellis Pharmaceuticals Soars on Blood-Drug Test
Jan 7, 2020 11:38 AM EST